Lupin Goa Facility Receives US FDA Form 483

Date: October 24, 2026

Regulatory Compliance Disclosure

Lupin Limited disclosed that the U.S. Food and Drug Administration (US FDA) conducted an inspection at the company's manufacturing facility located in Goa, India. The inspection took place from October 19, 2026, to October 23, 2026.

The inspection concluded with the issuance of a Form-483 containing one observation. The company stated it will address the observation and respond to the US FDA within the stipulated timeframe. Lupin reaffirmed its commitment to maintaining compliance with Current Good Manufacturing Practice (CGMP) standards across all its facilities.

Disclosure Basis

Not Specified Sections

No material disclosures under the following sections: Financial Results, Dividend Declaration, KMP/Board Changes, Board Meeting Outcomes, Auditor's Report, Disinvestment/Strategic Actions, Media Release/Investor Communication, Other Operational/Legal/Strategic Disclosures.